过氧化物酶体增殖物激活受体γ在冠心病患者血清中的表达及意义被引量：1

下载PDF

导出

摘要目的比较不同类型冠心病(CHD)患者血清过氧化物酶体增殖物激活受体γ(PPAR-γ)水平,探讨其与急性冠状动脉综合征(ACS)及冠状动脉狭窄程度之间的关系。方法选取CHD患者70例,其中稳定型心绞痛(SAP)组11例、不稳定型心绞痛(UAP)组44例、急性心肌梗死(AMI)组15例,按Gensini评分法评定其冠状动脉狭窄程度。另择13例冠状动脉造影正常者作为对照组。用酶联免疫吸附法(ELISA)测定各组血清PPAR-γ浓度。结果SAP组、UAP组和AMI组血清PPAR-γ水平分别为(640.23±348.92)、(653.55±341.32)、(783.93±294.22)pg/ml,均明显高于对照组的(583.93±294.22)pg/ml(P均<0.05);UAP组较SAP组轻度增高,但无统计学意义(P>0.05);AMI组较SAP组、UAP组显著增高(P均<0.05)。直线相关分析结果显示,年龄、性别、Gensini评分、吸烟史、高血压史、糖尿病史、TC、TG、HDL-C、LDL-C均与血清PPAR-γ无相关性(P均>0.05)。结论ACS患者血清PPAR-γ水平与冠状动脉内粥样硬化斑块的稳定性密切相关,有助于CHD的危险分层,对评价冠状动脉病变严重程度及预后可能具有重要意义。

作者田丽晓李凌贾启明陈晓杰杨一凌

机构地区郑州大学第一附属医院

出处《山东医药》 CAS 北大核心 2009年第9期46-47,共2页 Shandong Medical Journal

关键词冠状动脉疾病过氧化物酶体增殖物激活受体炎症

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1I Berger J, Moller DE. The mechanisms of action of PPARs[ J]. Ann Rev Med, 2002,53:409-435.
2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non- ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Assiociation Task Force on Practice Guidelines ( Committee on the Management of Patients with Unstable Angina)[ J]. J Am Coll Cardial, 2000, 36 (3):970-1062.
3Williams SV, Fihn SD, Gibbous RT. Guidelines for the management of plaques with chronic stable angina: diagnosis and risk stratification[ J]. Am Intern Med, 2001,135 (7) :530-547.
4GENSINI GG. A more meaningful scoriog system for determining the severity of corenary heart disease[J]. Am J Cardiol, 1983, 51 (3) : 606 -609.
5周明学,徐浩.过氧化物酶体增殖物激活受体-γ与易损斑块关系的研究进展[J].心血管病学进展,2007,28(4):610-612. 被引量：4
6Staels B. PPAR gamma and atherosclerosis [ J ]. Curr Med Res Opin, 2005,21 (3) :13-20.

二级参考文献22

1李崇剑,高润霖,杨跃进,陈纪林.易损斑块的病理生理机制及其检测的研究进展[J].中华心血管病杂志,2004,32(6):570-573. 被引量：88
2Berger J,Moler DE.The mechanisms of action of PPARs[J].Ann Rev Med,2002,339:953-959.
3Naghavi M,Libby P,Falk E,et al.From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part Ⅰ[J].Circulation,2003,108:1664-1672.
4van der Wal AC,Backer AE.Atherosclerotic plaque rupture pathologic basis of plaque stability and instability[J].Cardiovasc Res,1999,41:334-344.
5Lemaitre V,Soloway PD,D'Armiento J.Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1[J].Circulation,2003,107:333-338.
6Jiang C,Ting AT,Seed B.PPARγ agonists inhibit production of monocyte inflammatory cytokines[J].Nature,1998,391:82-86.
7Ricote M,LiA C,Willson TM,et al.The PPAR-gamma is a negative regulator of macrophage activation[J].Nature,1998,391:79-82.
8Marx N,Kehrle B,Kohlhammer K,et al.PPAR activators as anti-inflammatory mediator in human T lyphocytes:implications for atherosclerosis and translation associated artherosclerosis[J].Circ Res,2002,90(6):703-710.
9Li AC,Brown KK,Silvestre MJ,et al.Peroxisome proliferator activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice[J].J Clin Invest,2000,106:523-531.
10Kageyama H,Hirano T,Okada K,et al.Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma[J].Biochem Biophys Res Commun,2003,305:22-27.